Beyond Anti-Aging: AV Laboratories Puts Amino Acids at the Forefront of Science-Led Skin Longevity At the AVL Molecular Research Center at the University of Colorado Boulder, AV Laboratories has been studying skin cells to better understand what supports the visible…
Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, announced the…
Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammation Goldenrod Therapeutics, Inc., an innovator in brain inflammation treatments for multiple neurological conditions, announced that it has completed the initial closing under its $6.5 million Series Seed preferred…
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline Gilead Sciences, Inc. and Lakefront Biotherapeutics NV announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.…
Mevion Announces First Clinical Treatment on the MEVION S250-FIT™ Proton Therapy System Mevion Medical Systems, a global leader in compact proton therapy, announced that the world’s first clinical proton therapy treatment delivered inside an existing conventional radiation therapy vault has…
Sasol Advances Strategic Growth in Advanced Materials and Specialty Chemicals with €60 Million Brunsbüttel Investment Sasol International Chemicals announced a €60 million investment at its Brunsbüttel site to expand its advanced materials and specialty chemicals capabilities, reinforcing the company’s position…
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced that the first patient has been dosed…
CitroTech Expands Patent Portfolio, Leading the Market for GPS-Verified, AI-Enabled Deployment of Eco-Friendly Fire Retardants CitroTech announced the continued expansion of its intellectual property (IP) portfolio, reinforcing its position as the only company in wildfire prevention whose platform combines GPS-enabled…
Pittsburgh Paints Co. Introduces PITTSBURGH PAINTS Protective Coatings The Pittsburgh Paints Company launched the PITTSBURGH PAINTS™ Protective Coatings brand, the new face of PPG HIGH PERFORMANCE COATINGS™. In addition to the new brand’s offerings of industry-leading, full-system solutions, trusted products…
Nephrodite’s Holly™ Implantable Continuous Dialysis System Awarded Selection into FDA’s TAP to Accelerate Development and Patient Access Nephrodite, Inc., a medical device company developing an implantable, continuous renal replacement system, announced that its Holly™ system has been selected to participate in…
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy…
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) Gilead Sciences, Inc. announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with…